Drug Search Results
Using advanced filters...
Advanced Search [+]

Pracinostat

Alternative Names: pracinostat, sb939
Clinical Status: Inactive
Latest Update: 2024-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Helsinn Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Acute Myeloid Leukemia

Phase 2: Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Sarcoma|Myelofibrosis|Prostate Cancer|Myeloproliferative Disorders|Polycythemia Vera|Thrombocythemia, Essential

Phase 1: Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Leukemia|Tobacco Use Disorder|Oncology Solid Tumor Unspecified|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2016-004724-34

N/A

Terminated

Acute Myeloid Leukemia

2020-07-02

2025-06-17

Treatments

2006-7041-83/hah

N/A

Not yet recruiting

Suicidality

2019-01-31

PRO 33922

P1

Completed

Acute Myeloid Leukemia

2021-05-05

2022-07-01

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

PRAN-17-17

P1

Completed

Healthy Volunteers

2018-02-28

59%

2019-08-10

Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status

MEI-007

P1

Completed

Tobacco Use Disorder

2014-06-01

2024-11-27

Primary Endpoints

HVFE

P1

Completed

Tobacco Use Disorder

2014-03-01

2019-03-20

Treatments

I203

P1

Completed

Leukemia

2012-04-12

2023-08-05

Primary Endpoints|Start Date|Treatments

SB939-2006-001

P1

Completed

Myelodysplastic Syndrome|Preleukemia

2012-03-01

2019-03-18

Treatments

I188

P1

Completed

Oncology Solid Tumor Unspecified

2010-04-22

2023-08-05

Primary Endpoints|Start Date|Treatments

MEI-011

P2

Terminated

Preleukemia|Myelodysplastic Syndrome

2020-12-01

38%

2022-03-03

NCI-2015-00002

P2

Completed

Myelofibrosis|Myeloproliferative Disorders

2018-06-01

36%

2019-03-20

Treatments

MEI-004

P2

Completed

Acute Myeloid Leukemia

2016-11-08

2021-02-11

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments

MEI-003

P2

Completed

Myelodysplastic Syndrome|Preleukemia

2015-11-01

2019-03-19

Treatments

MEI-005

P2

Completed

Preleukemia|Myelodysplastic Syndrome

2015-05-01

2019-03-20

Treatments

I195

P2

Completed

Prostate Cancer

2015-01-05

2023-08-05

Primary Endpoints|Start Date|Treatments

IND200

P2

Completed

Sarcoma

2013-01-21

2023-08-05

Primary Endpoints|Start Date|Treatments

NCT01200498

P2

Completed

Thrombocythemia, Essential|Myelofibrosis|Polycythemia Vera|Myeloproliferative Disorders

2012-11-01

2019-03-19

Treatments

PRAN-16-52

P3

Terminated

Acute Myeloid Leukemia

2020-08-20

43%

2024-06-26

Primary Endpoints|Treatments

CTR20191971

P3

Terminated

Acute Myeloid Leukemia

None

2025-04-29

Patient Enrollment|Treatments|Trial Status